Literature DB >> 24804698

Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies.

Chien-Chang Liao1, Chao-Shun Lin1, Chun-Chuan Shih2, Chun-Chieh Yeh3, Yi-Cheng Chang4, Yuan-Wen Lee5, Ta-Liang Chen6.   

Abstract

OBJECTIVE: The relationship between diabetes and fracture is not completely understood. This study evaluated fracture risk and postfracture mortality in patients with diabetes. RESEARCH DESIGN AND METHODS: We identified 32,471 adults newly diagnosed with diabetes in 2000-2003 using Taiwan's National Health Insurance Research Database. A comparison cohort of 64,942 adults without diabetes was randomly selected from the same dataset, with frequency matched by age and sex. Fracture events in 2000-2008 were ascertained from medical claims. Adjusted hazard ratios (HRs) and 95% CIs of fracture associated with diabetes were calculated. A nested cohort study of 17,002 patients with fracture receiving repair surgeries between 2004 and 2010 calculated adjusted odds ratios (ORs) and 95% CIs of adverse events after fracture in patients with and without diabetes.
RESULTS: During 652,530 person-years of follow-up, there were 12,772 newly diagnosed fracture cases. The incidences of fracture for people with diabetes and without were 24.2 and 17.1 per 1,000 person-years, respectively (P < 0.0001). Compared with people without diabetes, the adjusted HR of fracture was 1.66 (95% CI 1.60-1.72) for people with diabetes. The ORs of postfracture deep wound infection, septicemia, and mortality associated with diabetes were 1.34 (95% CI 1.06-1.71), 1.42 (95% CI 1.23-1.64), and 1.27 (95% CI 1.02-1.60), respectively.
CONCLUSIONS: Diabetes was associated with fracture. Patients with diabetes had more adverse events and subsequent mortality after fracture. Prevention of fracture and postfracture adverse events is needed in this susceptible population.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Year:  2014        PMID: 24804698     DOI: 10.2337/dc13-2957

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  32 in total

1.  Bone histomorphometry in diabetes mellitus.

Authors:  C A Moreira; D W Dempster
Journal:  Osteoporos Int       Date:  2015-08-05       Impact factor: 4.507

2.  Change in estimated glomerular filtration rate and fracture risk in the Action to Control Cardiovascular Risk in Diabetes Trial.

Authors:  Tamara Isakova; Timothy E Craven; Julia J Scialla; Thomas L Nickolas; Adrian Schnall; Joshua Barzilay; Ann V Schwartz
Journal:  Bone       Date:  2015-04-30       Impact factor: 4.398

Review 3.  Epidemiology of Skeletal Health in Type 1 Diabetes.

Authors:  David R Weber; George Schwartz
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

4.  Risk and outcomes of fracture in peripheral arterial disease patients: two nationwide cohort studies.

Authors:  F-L Liu; C-S Lin; C-C Yeh; C-C Shih; Y-G Cherng; C-H Wu; T-L Chen; C-C Liao
Journal:  Osteoporos Int       Date:  2017-08-18       Impact factor: 4.507

Review 5.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

6.  Risk and adverse outcomes of fractures in patients with Parkinson's disease: two nationwide studies.

Authors:  Y-F Huang; Y-G Cherng; S P C Hsu; C-C Yeh; Y-C Chou; C-H Wu; T-L Chen; C-C Liao
Journal:  Osteoporos Int       Date:  2015-02-12       Impact factor: 4.507

Review 7.  Diabetes, bone and glucose-lowering agents: clinical outcomes.

Authors:  Ann V Schwartz
Journal:  Diabetologia       Date:  2017-04-27       Impact factor: 10.122

8.  An update on the role of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways in pediatric diseases.

Authors:  Giacomina Brunetti; Gabriele D'Amato; Mariangela Chiarito; Apollonia Tullo; Graziana Colaianni; Silvia Colucci; Maria Grano; Maria Felicia Faienza
Journal:  World J Pediatr       Date:  2018-10-20       Impact factor: 2.764

9.  Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE-/- mice.

Authors:  Lizhi Zhang; Peicheng Li; Zhaosheng Tang; Qin Dou; Bo Feng
Journal:  Ann Transl Med       Date:  2019-08

10.  Adverse outcomes after major surgery in patients with pressure ulcer: a nationwide population-based retrospective cohort study.

Authors:  Chia-Lun Chou; Woan-Ruoh Lee; Chun-Chieh Yeh; Chun-Chuan Shih; Ta-Liang Chen; Chien-Chang Liao
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.